시장보고서

상품코드

2077238

오르니틴 트랜스카바밀라제(OTC) 결핍증 치료 시장 : 약제 종류별, 투여 경로별, 유통 채널별, 지역별

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, by Drug Type, by Route of Administration, by Distribution Channel, and by Region

발행일: 2026년 04월 | 리서치사: 구분자

Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

가격

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,500

￦ 6,470,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 7,000

￦ 10,064,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,378,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

오르니틴 트랜스카바밀라제(OTC) 결핍증 치료 시장은 2026년에 9억 1,950만 달러 규모가 될 것으로 추정되며, 2033년까지 12억 4,710만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 4.5%로 성장할 것으로 전망됩니다.

보고서 범위		보고서 상세
기준 연도:	2025년	2026년 시장 규모:	9억 1,950만 달러
과거 데이터 기간:	2020-2024년	예측 기간:	2026-2033년
2026년부터 2033년까지 예측 기간 CAGR:	4.50%	2033년 시장 규모 예측:	12억 4,710만 달러

오르니틴 트랜스카바밀라제(OTC) 결핍증은 혈액 내에 과도한 암모니아가 축적되는(고암모니아혈증) 유전성 질환입니다. 암모니아 농도가 지나치게 높아지면, 그 독성으로 인해 신경계에 영향을 미칩니다. 이 질환의 징후나 증상으로는 활력 저하, 식욕 부진, 호흡 수 조절 장애, 체온 이상, 비정상적인 신체 움직임, 경련, 또는 혼수 상태 등이 포함될 수 있습니다. 이 질환은 남성과 여성 모두에게서 나타납니다. OTC는 OTC 유전자의 돌연변이에 의해 유발되며, X-연관 유전 방식으로 유전됩니다. 오르니틴 트랜스카바밀라제 결핍증으로 인한 합병증에는 발달 지연이나 지적 장애 등이 포함됩니다. 또한, 진행성 간 손상이 발생할 수도 있습니다.

시장 역학

시장 참여자들의 무기적 성장 전략이 증가함에 따라, 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2022년 9월, 후기 단계의 바이오의약품 기업인 GENFIT은 간 질환 분야에서 증가하는 미충족 의료 수요에 대응하는 데 주력하는 임상 단계의 바이오기술 기업인 Versantis의 전 지분 및 의결권을 취득하기 위한 독점 계약을 체결했다고 발표했습니다. 이 계약을 통해, 요소 순환 장애(UCD)에 초점을 맞춘 소아 대상 프로그램 'VS-01-UCD'가 추가됨에 따라 GENFIT의 파이프라인은 대폭 확대될 것입니다.

오르니틴 트랜스카바밀라제(OTC) 결핍증 치료제와 관련하여, 주요 기업들의 제품 출시 증가가 예측 기간 동안 시장 성장을 견인할 것으로 전망됩니다. 예를 들어, 2022년 9월, 제약회사인 Medunik USA는 페닐부틸레이트 나트륨(NaPB)을 함유한 독자적인 맛 가림 제제인 'Pheburane' 경구용 펠릿의 출시를 발표했습니다. 'Pheburane'는 처방약으로, 특정 식이요법과 병용하여 요소대사장애(UCD)를 가진 성인 및 소아의 장기 관리에 사용됩니다.

본 조사의 주요 특징:

본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 오르니틴 트랜스카바밀라제(OTC) 결핍증 시장의 주요 기업 개요을 소개하고 있습니다. 본 조사에서 다루고 있는 주요 기업으로는 Horizon Therapeutics Plc, Bausch Health Companies Inc., Danone, Nestle, Ultragenyx Pharmaceutical, Arcturus Therapeutics, Inc., Abbott, Swedish Orphan Biovitrum AB, Acer Therapeutics Inc., Assertio Holdings, Inc., iECURE, Translate Bio, Inc.가 포함됩니다.
본 보고서의 인사이트를 활용함으로써, 각 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
전 세계 오르니틴 트랜스카바밀라제(OTC) 결핍증 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
이해관계자 여러분은 전 세계 오르니틴 트랜스카바밀라제(OTC) 결핍증 치료 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 919.5 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.50%	2033 Value Projection:	USD 1,247.1 Mn

Ornithine transcarbamylase (OTC) deficiency is a genetic disorder that causes excessive ammonia buildup in the blood (hyperammonemia). When ammonia levels are too high, it is toxic and affects the nervous system. This signs and symptoms may also include lack of energy and appetite, an uncontrollable breathing rate, body temperature, unusual body movements, seizures, or coma. This form can be found in both males and females. OTC is caused by genetic changes in the OTC gene, and it is inherited in an X-linked manner. Complications from ornithine transcarbamylase deficiency may include developmental delay and intellectual disability. Progressive liver damage may also occur.

Market Dynamics

Increasing inorganic growth strategies by market players is expected to drive the market growth over the forecast period. For instance, in September 2022, GENFIT, a late-stage biopharmaceutical company, announced it had entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, is a clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases. This agreement significantly expands GENFIT's pipeline with VS-01-UCD, a pediatric program focused on urea cycle disorder (UCD).

Increasing product launches by key players for ornithine transcarbamylase (OTC) deficiency treatment is expected to drive the market growth over the forecast period. For instance, in September 2022, Medunik USA, a pharmaceutical company, announced the launch of Pheburane oral pellets, a unique taste-masked formulation of sodium phenylbutyrate (NaPB). Pheburane is a prescription medicine, used along with a specific diet, for the long-term management of adults and children with urea cycle disorders (UCDs).

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global ornithine transcarbamylase (OTC) deficiency market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Horizon Therapeutics Plc, Bausch Health Companies Inc., Danone, Nestle, Ultragenyx Pharmaceutical., Arcturus Therapeutics, Inc. , Abbott., Swedish Orphan Biovitrum AB, Acer Therapeutics Inc., Assertio Holdings, Inc., iECURE, and Translate Bio, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global ornithine transcarbamylase (OTC) deficiency market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ornithine transcarbamylase (OTC) deficiency treatment market.

Detailed Segmentation:

Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Drug Type (Revenue, USD Mn, 2021 - 2033)
Buphenyl
Ravicti
Ammonul
Others
Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
Oral
Intravenous
Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Distribution channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country:
  - U.S.
  - Canada
Latin America
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Country:
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Horizon Therapeutics Plc.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bausch Health Companies Inc
Danone
Nestle
Ultragenyx Pharmaceutical
Arcturus Therapeutics, Inc
Abbott
Swedish Orphan Biovitrum AB
Acer Therapeutics Inc
Assertio Holdings, Inc
iECURE
Translate Bio, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Regulatory Scenario
Market Trends
Key Developments
Epidemiology
PEST Analysis
Pipeline Analysis

4. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Drug Type, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Buphenyl
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)
Ravicti
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)
Ammonul
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)

5. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Route of Administration, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)

6. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Distribution Channel, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033,(US$ Mn)

7. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market, By Region, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033,(US$ Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033,(US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033,(US$ Mn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033,(US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033,(US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021-2033,(US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Competitive Snapshot
Heat Map Analysis
Market Share Analysis
- Horizon Therapeutics Plc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Bausch Health Companies Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Danone
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Nestle
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Ultragenyx Pharmaceutical.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Arcturus Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Swedish Orphan Biovitrum AB
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Acer Therapeutics Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Assertio Holdings, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- iECURE
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Translate Bio, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies

9. Section

Research Methodology
About us

오르니틴 트랜스카바밀라제(OTC) 결핍증 치료 시장 : 약제 종류별, 투여 경로별, 유통 채널별, 지역별